According to Capricorn, korkoat beads accommodate high drug loads; modified drug release can be achieved by incorporating release-modifying agents inside the bead, in the coating, or in both.
Rao Cherukuri, founder, president and CEO of Capricorn, said: “We are proud of our technologies, which offer flexible solutions to difficult formulation challenges. We believe this agreement further validates our commercialized oral drug delivery technology platforms and Capricorn’s proprietary encapsulation processes.”